About Globus Medical (NYSE:GMED)
Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address an array of spinal pathologies, anatomies, and surgical approaches. Its fusion products include a range of implant and surgical approach options to treat degenerative, deformity, tumor, and trauma conditions along the spine from the occiput to the sacrum. The company's disruptive technology products comprise products that allow for minimally invasive surgical techniques; and new treatment alternatives, including imaging, navigational, and robotic technologies, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous process spacer products. Its disruptive technology products also consist of regenerative biologics products, including bioactive glass-based bone void fillers and ceramic-collagen for pelvic/extremity and posterolateral spinal fusion procedures; and interventional pain management solutions, which comprise treatments for vertebral compression fractures. In addition, the company offers products for the treatment of orthopedic trauma, including compression screws, fixation plates, intramedullary nails, and external fixation systems. Further, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:GMED
CUSIP37957720
Phone610-930-1800
Debt
Debt-to-Equity RatioN/A
Current Ratio6.67%
Quick Ratio5.50%
Price-To-Earnings
Trailing P/E Ratio39.76
Forward P/E Ratio34.73
P/E Growth2.83
Sales & Book Value
Annual Sales$635.98 million
Price / Sales7.89
Cash Flow$1.8342 per share
Price / Cash28.40
Book Value$10.04 per share
Price / Book5.19
Profitability
EPS (Most Recent Fiscal Year)$1.31
Net Income$107.34 million
Net Margins16.88%
Return on Equity13.93%
Return on Assets12.59%
Miscellaneous
Employees1,500
Outstanding Shares96,380,000
Globus Medical (NYSE:GMED) Frequently Asked Questions
What is Globus Medical's stock symbol?
Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."
How were Globus Medical's earnings last quarter?
Globus Medical Inc (NYSE:GMED) issued its quarterly earnings data on Wednesday, February, 21st. The medical device company reported $0.38 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.03. The medical device company had revenue of $176.03 million for the quarter, compared to analyst estimates of $175.50 million. Globus Medical had a net margin of 16.88% and a return on equity of 13.93%. The company's revenue for the quarter was up 16.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.31 earnings per share. View Globus Medical's Earnings History.
When is Globus Medical's next earnings date?
What guidance has Globus Medical issued on next quarter's earnings?
Globus Medical updated its FY18 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of approx $1.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.50. The company issued revenue guidance of approx $690 million, compared to the consensus revenue estimate of $690.85 million.
What price target have analysts set for GMED?
11 brokers have issued 1-year target prices for Globus Medical's shares. Their forecasts range from $36.00 to $60.00. On average, they expect Globus Medical's share price to reach $49.50 in the next twelve months. View Analyst Ratings for Globus Medical.
What are Wall Street analysts saying about Globus Medical stock?
Here are some recent quotes from research analysts about Globus Medical stock:
- 1. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (3/13/2018)
- 2. Canaccord Genuity analysts commented, "We recently had the opportunity to host a fireside chat with Globus, as well as visit the company’s booth during the AAOS conference and came away incrementally more confident in the growth opportunities ahead of the company. Specifically, early feedback and success with the ExcelsiusGPS system reinforce our view that the robotic platform can provide a tailwind to an improving core US spine business. In trauma, we were encouraged by the early excitement around the initial product launches – including 6 recently cleared systems to complement the 5 launched at OTA back in October – which we expect to develop into a growth driver in 2019 and beyond. Net, net, while the valuation certainly reflects continued execution in 2018, we are increasingly optimistic that the improving fundamentals in the core US spine business, early success in robotics, and OUS momentum are capable of delivering continued upside to current guidance – thus supporting continued share appreciation." (3/12/2018)
- 3. Needham & Company LLC analysts commented, "GMED’s 4Q17 revenue was consistent with its 1/9/18 preannouncement and its EPS beat consensus. Management reiterated 2018 revenue guidance of $690M and adjusted EPS guidance of $1.50. We estimate that the Emerging Technology segment drove much of the upside given the incremental revenue and negligible EPS drag. Gross margin was up 250 bps Y/Y and operating margin was up 60 bps Y/Y. We maintain our Hold rating since we believe that GMED’s valuation appropriately reflects its Emerging Technologies business’ potential." (2/22/2018)
Who are some of Globus Medical's key competitors?
Some companies that are related to Globus Medical include Dexcom (DXCM), Hill-Rom (HRC), Insulet (PODD), ICU Medical (ICUI), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), Nevro (NVRO), NuVasive (NUVA), Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR) and Glaukos (GKOS).
Who are Globus Medical's key executives?
Globus Medical's management team includes the folowing people:
- Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 51)
- Mr. David M. Demski, CEO, Group Pres of Emerging Technologies & Director (Age 60)
- Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 47)
- Mr. David D. Davidar, Co-Founder & Director (Age 52)
- Mr. Daniel T. Scavilla, CFO & Sr. VP (Age 53)
Has Globus Medical been receiving favorable news coverage?
News coverage about GMED stock has been trending somewhat positive on Saturday, according to Accern. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Globus Medical earned a media sentiment score of 0.12 on Accern's scale. They also assigned news coverage about the medical device company an impact score of 48.08 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Globus Medical?
Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Globus Medical's stock price today?
One share of GMED stock can currently be purchased for approximately $52.09.
How big of a company is Globus Medical?
Globus Medical has a market capitalization of $4.92 billion and generates $635.98 million in revenue each year. The medical device company earns $107.34 million in net income (profit) each year or $1.31 on an earnings per share basis. Globus Medical employs 1,500 workers across the globe.
How can I contact Globus Medical?
Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]
MarketBeat Community Rating for Globus Medical (GMED)
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
Globus Medical (NYSE:GMED) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Globus Medical in the last 12 months. Their average twelve-month price target is $49.50, suggesting that the stock has a possible downside of 4.97%. The high price target for GMED is $60.00 and the low price target for GMED is $36.00. There are currently 1 sell rating, 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 2.55 | 2.55 | 2.58 | 2.38 |
| Ratings Breakdown: | 1 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $49.50 | $48.8333 | $40.5714 | $30.5714 |
| Price Target Upside: | 4.97% downside | 5.25% downside | 9.56% downside | 1.33% upside |
Globus Medical (NYSE:GMED) Consensus Price Target History
Globus Medical (NYSE:GMED) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Globus Medical (NYSE:GMED) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Globus Medical (NYSE GMED) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.21%
Institutional Ownership Percentage: 65.85%
Globus Medical (NYSE GMED) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/19/2018 | David M Demski | CEO | Sell | 149,109 | $51.00 | $7,604,559.00 | 192,018 |  |
| 4/13/2018 | David M Demski | CEO | Sell | 50,891 | $51.00 | $2,595,441.00 | 152,701 | |
| 4/10/2018 | Daniel T Scavilla | VP | Sell | 100,000 | $50.00 | $5,000,000.00 | 18,210 | |
| 3/28/2018 | Eric Schwartz | VP | Sell | 24,000 | $50.00 | $1,200,000.00 | 24,000 | |
| 12/15/2017 | Steven Payne | CAO | Sell | 3,076 | $39.30 | $120,886.80 | 23,847 | |
| 12/13/2017 | Anthony L Williams | President | Sell | 15,000 | $38.30 | $574,500.00 | 15,000 | |
| 12/4/2017 | David D Davidar | Director | Sell | 55,383 | $40.66 | $2,251,872.78 | 752,236 | |
| 11/9/2017 | A Brett Murphy | Insider | Sell | 51,449 | $35.00 | $1,800,715.00 | 49,768 | |
| 9/6/2017 | A Brett Murphy | Insider | Sell | 15,000 | $29.99 | $449,850.00 | 101,217 | |
| 6/5/2017 | Anthony L Williams | President | Sell | 16,153 | $31.94 | $515,926.82 | 16,153 | |
| 8/5/2016 | A Brett Murphy | Insider | Sell | 107,692 | $23.37 | $2,516,762.04 | 190,917 | |
| 1/6/2016 | Robert Liptak | Director | Sell | 15,300 | $27.50 | $420,750.00 | 26,159 | |
| 1/4/2016 | Kurt Wheeler | Director | Sell | 255 | $27.50 | $7,012.50 | 44,319 | |
| 5/28/2015 | Steven Payne | CAO | Sell | 3,076 | $25.92 | $79,729.92 | | |
| 3/19/2015 | David C Paul | CEO | Sell | 1,922,000 | $25.00 | $48,050,000.00 | | |
| 1/15/2014 | David Demski | COO | Sell | 96,813 | $20.51 | $1,985,634.63 | 381,365 | |
| 12/31/2013 | David Demski | COO | Sell | 3,187 | $20.25 | $64,536.75 | 478,178 | |
| 12/20/2013 | David Demski | COO | Sell | 50,000 | $19.75 | $987,500.00 | 481,365 | |
| 12/6/2013 | Robert Liptak | Director | Sell | 25,000 | $19.36 | $484,000.00 | 26,159 | |
| 12/3/2013 | David Davidar | VP | Sell | 75,000 | $19.25 | $1,443,750.00 | 897,275 | |
| 11/27/2013 | David Demski | COO | Sell | 37,323 | $19.25 | $718,467.75 | 531,365 | |
| 11/1/2013 | David M Demski | COO | Sell | 112,677 | $18.59 | $2,094,665.43 | | |
| 8/23/2013 | David Davidar | VP | Sell | 7,278 | $18.20 | $132,459.60 | 997,499 | |
| 8/22/2013 | David Demski | COO | Sell | 44,154 | $17.95 | $792,564.30 | 681,365 | |
| 7/5/2013 | David D Davidar | VP | Sell | 10,000 | $17.15 | $171,500.00 | | |
| 7/1/2013 | David D Davidar | VP | Sell | 20,000 | $16.56 | $331,200.00 | | |
| 6/26/2013 | David D Davidar | VP | Sell | 150,000 | $16.71 | $2,506,500.00 | | |
| 8/8/2012 | David C Paul | CEO | Sell | 3,039,385 | $11.16 | $33,919,536.60 | | |
| 8/8/2012 | David D Davidar | VP | Sell | 166,885 | $11.16 | $1,862,436.60 | | |
| 8/8/2012 | David M Demski | COO | Sell | 98,957 | $11.16 | $1,104,360.12 | | |
| 8/8/2012 | Kurt Wheeler | Director | Sell | 804,232 | $11.16 | $8,975,229.12 | | |
| 8/8/2012 | Steven Payne | CAO | Sell | 2,305 | $11.16 | $25,723.80 | | |
(Data available from 1/1/2013 forward)
Globus Medical (NYSE GMED) News Headlines
| Source: |
|
Globus Medical (NYSE:GMED) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Globus Medical (NYSE:GMED) Income Statement, Balance Sheet and Cash Flow Statement
Globus Medical (NYSE GMED) Stock Chart for Saturday, April, 21, 2018
Loading chart…
